Critical Comparison: Viveve Medical (VIVE) & Its Rivals
Viveve Medical (NASDAQ: VIVE) is one of 83 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Viveve Medical to similar businesses based on the strength of its earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
This is a breakdown of recent recommendations and price targets for Viveve Medical and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Viveve Medical Competitors||267||1856||3319||105||2.59|
Viveve Medical currently has a consensus target price of $10.50, indicating a potential upside of 94.81%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 4.31%. Given Viveve Medical’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Viveve Medical is more favorable than its competitors.
Valuation & Earnings
This table compares Viveve Medical and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Viveve Medical||$7.14 million||-$20.11 million||-2.54|
|Viveve Medical Competitors||$2.13 billion||$221.25 million||-13.19|
Viveve Medical’s competitors have higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
65.5% of Viveve Medical shares are held by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 35.1% of Viveve Medical shares are held by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares Viveve Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Viveve Medical Competitors||-299.57%||-36.17%||-12.71%|
Risk and Volatility
Viveve Medical has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500. Comparatively, Viveve Medical’s competitors have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
Viveve Medical Company Profile
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.